{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:12:26Z","timestamp":1789135946941,"version":"build-2803163510"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81973387"],"award-info":[{"award-number":["81973387"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Significant variations in tacrolimus (TAC) pharmacokinetics (PK) occur across whole blood, plasma, and peripheral blood mononuclear cells (PBMCs). In the present study, TAC plasma levels were estimated based on TAC whole blood levels, and the influence of genetic polymorphisms on the PKs of TAC were compared between whole blood, plasma, and PBMCs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Whole blood, plasma, and PBMC samples of 36 kidney allograft recipients were collected at 0\u201312 hours after the morning dose after 1 month of therapy. TAC levels in whole blood (C\n                      <jats:sub>wb<\/jats:sub>\n                      ), plasma (C\n                      <jats:sub>p<\/jats:sub>\n                      ), and PBMCs were determined using liquid chromatography\u2013tandem mass spectrometry. TAC C\n                      <jats:sub>p<\/jats:sub>\n                      was estimated based on C\n                      <jats:sub>wb<\/jats:sub>\n                      and hematocrit. PK parameters of TAC in whole blood, plasma, and PBMC were estimated. The influence of\n                      <jats:italic toggle=\"yes\">CYP3A5<\/jats:italic>\n                      and\n                      <jats:italic toggle=\"yes\">ABCB1<\/jats:italic>\n                      genotypes on TAC exposure was evaluated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      TAC whole blood trough concentration (C\n                      <jats:sub>0<\/jats:sub>\n                      ), maximum concentration (C\n                      <jats:sub>max<\/jats:sub>\n                      ), and area under the concentration\u2013time curve (AUC\n                      <jats:sub>0\u201312<\/jats:sub>\n                      ) were 8.60 \u00b1 5.59 ng\/mL, 20.1 \u00b1 7.69 ng\/mL, and 144 \u00b1 69.4 ng\u22c5h\/mL, respectively; 0.21 \u00b1 0.12 ng\/mL, 0.51 \u00b1 0.35 ng\/mL, and 3.02 \u00b1 1.68 ng\u22c5h\/mL, respectively, in plasma; and 0.026 \u00b1 0.017 ng\/10\n                      <jats:sup>6<\/jats:sup>\n                      PBMCs, 0.078 \u00b1 0.047 ng\/10\n                      <jats:sup>6<\/jats:sup>\n                      PBMCs, 0.49 \u00b1 0.30 ng\u22c5h\/10\n                      <jats:sup>6<\/jats:sup>\n                      PBMCs, respectively. A moderate correlation was observed between C\n                      <jats:sub>0<\/jats:sub>\n                      , C\n                      <jats:sub>max<\/jats:sub>\n                      , and AUC\n                      <jats:sub>0\u201312<\/jats:sub>\n                      in plasma and PBMCs (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05). Recipients with\n                      <jats:italic toggle=\"yes\">CYP3A5*3\/*3<\/jats:italic>\n                      genotype exhibited a higher AUC\n                      <jats:sub>0\u201312<\/jats:sub>\n                      in PBMC than those with the *1\/*1 or *1\/*3 genotypes (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05). Recipients with\n                      <jats:italic toggle=\"yes\">ABCB1<\/jats:italic>\n                      3435 TT genotype showed higher C\n                      <jats:sub>0<\/jats:sub>\n                      , C\n                      <jats:sub>max<\/jats:sub>\n                      , and AUC\n                      <jats:sub>0\u201312<\/jats:sub>\n                      values in PBMC than those with the 3435CC or CT genotypes (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      Plasma TAC concentrations in Chinese kidney allograft recipients can be estimated using whole blood TAC and hematocrit levels. Genetic polymorphisms of\n                      <jats:italic toggle=\"yes\">CYP3A5*3<\/jats:italic>\n                      and\n                      <jats:italic toggle=\"yes\">ABCB1<\/jats:italic>\n                      (3435C &gt; T) significantly influenced TAC exposure in both plasma and PBMC.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001459","type":"journal-article","created":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T03:00:09Z","timestamp":1776481209000},"page":"605-612","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Influence of Genetic Polymorphisms on Tacrolimus Pharmacokinetics in Whole Blood, Plasma, and Peripheral Blood Mononuclear Cells in Chinese Kidney Allograft Recipients"],"prefix":"10.1097","volume":"48","author":[{"given":"Yun-Zhu","family":"Lu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Ruijin Hospital, Jiaotong University School of Medicine, Shanghai, P.R. China; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Ling","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Ruijin Hospital, Jiaotong University School of Medicine, Shanghai, P.R. China; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ping","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Ruijin Hospital, Jiaotong University School of Medicine, Shanghai, P.R. China; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Qian","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Ruijin Hospital, Jiaotong University School of Medicine, Shanghai, P.R. China; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Shao","sequence":"additional","affiliation":[{"name":"Center of Organ Transplantation, Ruijin Hospital, Jiaotong University School of Medicine, Shanghai, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Min","family":"An","sequence":"additional","affiliation":[{"name":"Center of Organ Transplantation, Ruijin Hospital, Jiaotong University School of Medicine, Shanghai, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Qiang","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Ruijin Hospital, Jiaotong University School of Medicine, Shanghai, P.R. China; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Jun","family":"Zhou","sequence":"additional","affiliation":[{"name":"Center of Organ Transplantation, Ruijin Hospital, Jiaotong University School of Medicine, Shanghai, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4909-4792","authenticated-orcid":false,"given":"Bing","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Ruijin Hospital, Jiaotong University School of Medicine, Shanghai, P.R. China; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"R1-20260911","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/phar.2481","article-title":"Immunosuppression trends in solid organ transplantation: the future of individualization, monitoring, and management","volume":"41","author":"Pilch","year":"2021","journal-title":"Pharmacotherapy"},{"key":"R2-20260911","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1681\/ASN.2014060588","article-title":"Disappearance of T cell-mediated rejection despite continued antibody-mediated rejection in late kidney transplant recipients","volume":"26","author":"Halloran","year":"2015","journal-title":"J Am Soc Nephrol."},{"key":"R3-20260911","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2165\/00003495-199754060-00009","article-title":"Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation","volume":"54","author":"Spencer","year":"1997","journal-title":"Drugs"},{"issue":"suppl 1","key":"R4-20260911","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1097\/FTD.0000000000000234","article-title":"Nuclear factor of activated T cells-regulated gene expression as predictive biomarker of personal response to calcineurin inhibitors","volume":"38","author":"Sommerer","year":"2016","journal-title":"Ther Drug Monit."},{"key":"R5-20260911","doi-asserted-by":"crossref","first-page":"404","DOI":"10.2165\/00003088-199529060-00003","article-title":"Clinical pharmacokinetics of tacrolimus","volume":"29","author":"Venkataramanan","year":"1995","journal-title":"Clin Pharmacokinet."},{"key":"R6-20260911","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1111\/cts.12833","article-title":"Fasting status and circadian variation must be considered when performing AUC-based therapeutic drug monitoring of tacrolimus in renal transplant recipients","volume":"13","author":"Gustavsen","year":"2020","journal-title":"Clin Transl Sci."},{"key":"R7-20260911","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","article-title":"Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report","volume":"41","author":"Brunet","year":"2019","journal-title":"Ther Drug Monit."},{"key":"R8-20260911","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.phrs.2017.12.005","article-title":"Comparative clinical trial of the variability factors of the exposure indices used for the drug monitoring of two tacrolimus formulations in kidney transplant recipients","volume":"129","author":"Marquet","year":"2018","journal-title":"Pharmacol Res."},{"key":"R9-20260911","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40262-019-00854-1","article-title":"Unbound plasma, total plasma, and whole-blood tacrolimus pharmacokinetics early after thoracic organ transplantation","volume":"59","author":"Sikma","year":"2020","journal-title":"Clin Pharmacokinet."},{"key":"R10-20260911","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.chroma.2018.03.010","article-title":"A simple and highly sensitive on-line column extraction liquid chromatography-tandem mass spectrometry method for the determination of protein-unbound tacrolimus in human plasma samples","volume":"1547","author":"Bittersohl","year":"2018","journal-title":"J Chromatogr A."},{"key":"R11-20260911","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00228-013-1584-7","article-title":"Importance of hematocrit for a tacrolimus target concentration strategy","volume":"70","author":"St\u00f8rset","year":"2014","journal-title":"Eur J Clin Pharmacol."},{"key":"R12-20260911","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1097\/TP.0b013e318278d367","article-title":"Interpreting tacrolimus concentrations during pregnancy and postpartum","volume":"95","author":"Hebert","year":"2013","journal-title":"Transplantation"},{"key":"R13-20260911","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/FTD.0000000000000982","article-title":"Association between the intracellular tacrolimus concentration in CD3 + T lymphocytes and CD14 + monocytes and acute kidney transplant rejection","volume":"44","author":"Udomkarnjananun","year":"2022","journal-title":"Ther Drug Monit."},{"key":"R14-20260911","doi-asserted-by":"crossref","first-page":"733285","DOI":"10.3389\/fphar.2021.733285","article-title":"Monitoring intra-cellular tacrolimus concentrations in solid organ transplantation: use of peripheral blood mononuclear cells and graft biopsy tissue","volume":"12","author":"Sallustio","year":"2021","journal-title":"Front Pharmacol."},{"key":"R15-20260911","doi-asserted-by":"crossref","first-page":"e0230195","DOI":"10.1371\/journal.pone.0230195","article-title":"Pharmacogenetic-whole blood and intracellular pharmacokinetic-pharmacodynamic (PG-PK2-PD) relationship of tacrolimus in liver transplant recipients","volume":"15","author":"Tron","year":"2020","journal-title":"PLoS One"},{"key":"R16-20260911","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s40262-018-0717-7","article-title":"Pharmacogenetics of membrane transporters of tacrolimus in solid organ transplantation","volume":"58","author":"Tron","year":"2019","journal-title":"Clin Pharmacokinet."},{"key":"R17-20260911","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/FTD.0000000000000765","article-title":"Establishment of a liquid chromatography-tandem mass spectrometry method for the determination of immunosuppressant levels in the peripheral blood mononuclear cells of Chinese renal transplant recipients","volume":"42","author":"Chen","year":"2020","journal-title":"Ther Drug Monit."},{"key":"R18-20260911","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/jcla.20299","article-title":"Detection of C1236T, G2677T\/A, and C3435T polymorphism of MDR1 by amplification refractory mutation system PCR","volume":"23","author":"Chen","year":"2009","journal-title":"J Clin Lab Anal."},{"key":"R19-20260911","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0009-9236(95)90153-1","article-title":"Pharmacokinetics of tacrolimus in liver transplant patients","volume":"57","author":"Jusko","year":"1995","journal-title":"Clin Pharmacol Ther."},{"key":"R20-20260911","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00467-018-4117-x","article-title":"The potential impact of hematocrit correction on evaluation of tacrolimus target exposure in pediatric kidney transplant patients","volume":"34","author":"Schijvens","year":"2019","journal-title":"Pediatr Nephrol."},{"key":"R21-20260911","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1097\/TP.0b013e3181a23cb2","article-title":"The challenge of achieving target drug concentrations in clinical trials: experience from the symphony study","volume":"87","author":"Ekberg","year":"2009","journal-title":"Transplantation"},{"key":"R22-20260911","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/clpt.2012.109","article-title":"In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients","volume":"92","author":"de Jonge","year":"2012","journal-title":"Clin Pharmacol Ther."},{"key":"R23-20260911","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/bcp.12361","article-title":"Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling","volume":"78","author":"Storset","year":"2014","journal-title":"Br J Clin Pharmacol."},{"key":"R24-20260911","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jpba.2018.01.002","article-title":"UPLC-MS\/MS assay validation for tacrolimus quantitative determination in peripheral blood T CD4+ and B CD19+ lymphocytes","volume":"152","author":"Romano","year":"2018","journal-title":"J Pharm Biomed Anal."},{"key":"R25-20260911","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s00228-021-03215-9","article-title":"The pharmacokinetics of tacrolimus in peripheral blood mononuclear cells and limited sampling strategy for estimation of exposure in renal transplant recipients","volume":"78","author":"Wang","year":"2022","journal-title":"Eur J Clin Pharmacol."},{"key":"R26-20260911","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0022-3565(24)29199-0","article-title":"Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos","volume":"299","author":"Dai","year":"2001","journal-title":"J Pharmacol Exp Ther."},{"key":"R27-20260911","first-page":"268","article-title":"Novel mutations of CYP3A4 in Chinese","volume":"29","author":"Hsieh","year":"2001","journal-title":"Drug Metab Dispos."},{"key":"R28-20260911","doi-asserted-by":"crossref","first-page":"398","DOI":"10.2133\/dmpk.DMPK-12-RG-148","article-title":"Effect of CYP3A5*3 polymorphism on pharmacokinetic drug interaction between tacrolimus and amlodipine","volume":"28","author":"Zuo","year":"2013","journal-title":"Drug Metab Pharmacokinet."},{"key":"R29-20260911","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/FTD.0b013e31829f1ab8","article-title":"Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose","volume":"36","author":"Bergmann","year":"2014","journal-title":"Ther Drug Monit."},{"key":"R30-20260911","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/bcpt.12176","article-title":"Population pharmacokinetic-pharmacogenetic model of tacrolimus in the early period after kidney transplantation","volume":"114","author":"Han","year":"2014","journal-title":"Basic Clin Pharmacol Toxicol."},{"key":"R31-20260911","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/cpt.113","article-title":"Clinical pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing","volume":"98","author":"Birdwell","year":"2015","journal-title":"Clin Pharmacol Ther."},{"key":"R32-20260911","doi-asserted-by":"crossref","first-page":"e0153491","DOI":"10.1371\/journal.pone.0153491","article-title":"Monitoring the intracellular tacrolimus concentration in kidney transplant recipients with stable graft function","volume":"11","author":"Han","year":"2016","journal-title":"PLoS One"},{"key":"R33-20260911","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1373\/clinchem.2005.050047","article-title":"Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus","volume":"51","author":"Kamdem","year":"2005","journal-title":"Clin Chem."},{"key":"R34-20260911","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1046\/j.1365-2036.2002.01238.x","article-title":"P-glycoprotein-170 inhibition significantly reduces cortisol and ciclosporin efflux from human intestinal epithelial cells and T lymphocytes","volume":"16","author":"Farrell","year":"2002","journal-title":"Aliment Pharmacol Ther."},{"key":"R35-20260911","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2217\/pgs.10.43","article-title":"CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation","volume":"11","author":"Capron","year":"2010","journal-title":"Pharmacogenomics"},{"key":"R36-20260911","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1432-2277.2011.01365.x","article-title":"Correlation of tacrolimus levels in peripheral blood mononuclear cells with histological staging of rejection after liver transplantation: preliminary results of a prospective study","volume":"25","author":"Capron","year":"2012","journal-title":"Transpl Int."},{"key":"R37-20260911","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/FTD.0b013e31828c1581","article-title":"Genetic polymorphisms in ABCB1 influence the pharmacodynamics of tacrolimus","volume":"35","author":"Vafadari","year":"2013","journal-title":"Ther Drug Monit."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001459","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:00:32Z","timestamp":1789135232000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001459","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"2025-02-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}